Novo Nordisk announced that the FDA has granted clearance for the insulin pen device NovoPen Echo, the first pen device with half-unit dosing and a memory function that records the dose and elapsed time.
NovoPen Echo will be available to patients for use with NovoLog (insulin aspart [rDNA origin] injection) PenFill cartridges. NovoLog is a fast-acting man-made insulin that binds to insulin receptors on muscle and fat cells, and lowers blood glucose by facilitating the cellular uptake of glucose. It also simultaneously inhibits the output of glucose from the liver.
Half-unit dose increments allow for more detailed adjustments, which can be particularly important for the pediatric population. Also, different removable skins will be available for a kid-friendly customized look.
Novo Nordisk anticipates product availability in early 2014.
For more information call (800) 727-6500 or visit Novonordisk-us.com.